top of page
Active, not recruiting

NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 Relapsed Refractory Myeloma

Updated: Feb 10

  • NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma


CTX120 crispr therapeutics

This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple myeloma.


Sponsor


Multiple locations

International study

 

ClinicalTrials.gov Identifier: NCT04244656


A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) in Subjects With Relapsed or Refractory Multiple Myeloma


First Posted : January 28, 2020


Click here for details on ClinicalTrials.gov

 

Biological: CTX120

CRISPR/Cas9 gene-edited allogeneic anti-BCMA CAR-T cells CTX120

allogeneic CRISPR-Cas9 engineered anti-BCMA T cells CTX120


CTX120 B-cell maturation antigen (BCMA)-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.


Description: CTX120 is an allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy targeting BCMA in development for the treatment of multiple myeloma

Gene editing approach: Disruption and insertion


 

- Multiple locations

- Illinois: University of Chicago

- Pennsylvania: University of Pennsylvania Philadelphia

- Tennessee: Sarah Cannon Research Institute Nashville

 

Locations

United States, Illinois

United States, Oregon

United States, Pennsylvania

United States, Tennessee

Canada, Ontario

Australia, New South Wales

Australia, Victoria

Spain


Posts Archive
bottom of page